Infant Bacterial Therapeutics AB (OSTO:IBT B) Total Payout Ratio : 0.02 (As of Jul. 23, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Infant Bacterial Therapeutics AB's current Total Payout Ratio is 0.02.

Infant Bacterial Therapeutics AB Total Payout Ratio Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Total Payout Ratio Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Payout Ratio

Get a 7-Day Free Trial

0.03

0.75

0.01

Infant Bacterial Therapeutics AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Payout Ratio	Get a 7-Day Free Trial															-	0.05	-	-	-

Competitive Comparison of Infant Bacterial Therapeutics AB's Total Payout Ratio

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Total Payout Ratio falls into.

Save Embed

;

Save Embed

;

Infant Bacterial Therapeutics AB Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Infant Bacterial Therapeutics AB's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	2.013	+	0)	/	-145.343
	=	0.01

Infant Bacterial Therapeutics AB's Total Payout Ratio for the quarter that ended in Mar. 2025 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0	+	0)	/	-17.495
	=	0.00

Infant Bacterial Therapeutics AB Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines